Spinning off, Reorganizing and Strengthening the R&D Division
First written in FY2017. 10 of 23 entries say "Advanced", first in FY2018-Q3. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Full-year decline in revenue and swing to a lossAnnual report
「Revenue from the research and development and analysis business declined to ¥73 million, down ¥16 million, or 18.4%, year on year, mainly because growth in commissioned analysis contracts stalled. Segment loss (ordinary loss) was ¥12 million, largely due to the increased personnel cost burden, compared with segment profit (ordinary profit) of ¥12 million in the previous year.」
Due to sluggish commissioned analysis and a higher personnel cost burden, full-year revenue from the research and development and analysis business fell 18.4%, and the business swung from profit of ¥12 million in the previous year to a loss of ¥12 million. - 2026-05-13WorsenedEarnings
「Revenue from research and development and analytical services declined by ¥16 million, or 18.4%, year on year to ¥73 million, mainly because growth in winning contract analysis work stalled. The segment loss (ordinary loss) was ¥12 million, largely due to the increase in personnel costs, compared with segment profit (ordinary profit) of ¥12 million in the previous fiscal year.」
The research and development and analytical services business fell from profit into loss as the acquisition of contract analysis work stagnated. - FY2026-H1Commissioned analysis stalled and the segment swung to a lossAnnual report
「As the commissioned analysis business remained sluggish, revenue declined to ¥37 million, down ¥4 million, or 10.2%, year on year. The segment recorded a loss of ¥6 million, or ordinary loss, due to the impact of higher personnel costs, compared with segment profit (ordinary profit) of ¥3 million in the previous year.」
The research and development and analysis business swung from profit of ¥3 million in the previous year to a loss of ¥6 million due to sluggish commissioned analysis and higher personnel costs. - FY2024AchievedAnnual report
「株式会社メディカル青果物研究所 was absorbed into デザイナーフーズ株式会社 effective 1 April 2024 and ceased to exist.」
The integration plan for the research and development and analysis business was implemented on 1 April 2024, completing the restructuring with デザイナーフーズ as the surviving company. - FY2024-Q3AdvancedAnnual report
「At a meeting of the Board of Directors held on 14 December 2023, the company approved a resolution to conduct an absorption-type merger under which its consolidated subsidiary デザイナーフーズ㈱ would be the surviving company and its consolidated subsidiary ㈱メディカル青果物研究所 would be the absorbed company. The two companies entered into a merger agreement on 15 January 2024.」
Regarding the restructuring of the research and development and analysis business, the company proceeded to approve and execute an absorption-type merger agreement, with デザイナーフーズ as the surviving company. The integration, scheduled for 1 April 2024, is intended to foster collaboration between research and analysis operations and consulting operations. - FY2024-Q2Revenue down, but loss narrowedAnnual report
「Although orders for commissioned analysis, including validation testing for major companies, increased, revenue declined to ¥48 million, down ¥1 million, or 3.6%, year on year, due in part to the failure to secure public subsidy projects. Segment loss (ordinary loss) was ¥1 million, compared with a segment loss (ordinary loss) of ¥2 million in the previous year, as lower personnel costs and other factors offset the impact of lower revenue.」
Although orders for validation testing from major companies increased, revenue fell 3.6% year on year because progress in securing public subsidy projects was limited. The segment loss narrowed from ¥2 million to ¥1 million due to lower personnel costs. - FY2024-Q1AdvancedAnnual report
「Although the number of regular consulting contracts increased, revenue rose to ¥27 million, up ¥1 million, or 7.9%, year on year, as the decline in commissioned analysis projects was more than offset. Segment loss (ordinary loss) was ¥0 million, compared with a segment loss (ordinary loss) of ¥1 million in the same quarter of the previous year, due to higher personnel costs resulting from increased staffing and other factors.」
Revenue rose 7.9% year on year due to an increase in regular consulting contracts, while the segment loss narrowed from ¥1 million in the previous year to ¥0 million. - FY2023-Q3More commissioned analyses and consulting, but losses continued amid fewer intra-group research contracts and increased staffingAnnual report
「Revenue increased from commissioned analysis projects, including validation testing orders from major companies, and public subsidy programs, while the consulting business also performed steadily, with an increase in regular consulting contracts. However, revenue declined to ¥74 million, down ¥2 million, or 3.7%, year on year, mainly due to a decrease in research contracts within the group. Segment loss (ordinary loss) was ¥6 million, largely due to higher personnel costs resulting from increased staffing and other factors, compared with segment profit (ordinary profit) of ¥6 million in the same quarter of the previous year.」
Although commissioned analyses, public subsidy programs and regular consulting increased, revenue fell 3.7% year on year due to a decline in intra-group research contracts, and the segment incurred a ¥6 million loss due to higher personnel costs resulting from increased staffing and other factors. - FY2023-Q2More commissioned analyses and consulting, but losses continuedAnnual report
「Revenue increased through commissioned analysis projects, including validation testing for major companies, and public subsidy programs. The consulting business also performed steadily, with an increase in regular consulting contracts. Revenue was ¥50 million, up ¥0 million, or 1.5%, year on year. Despite higher personnel costs resulting from increased staffing and other factors, the increase in revenue resulted in a segment loss (ordinary loss) of ¥2 million, compared with segment profit (ordinary profit) of ¥4 million in the same quarter of the previous year.」
Although orders increased for validation testing by major companies, public subsidy programs and regular consulting, the segment incurred a ¥2 million loss due to higher personnel costs resulting from increased staffing and other factors. - FY2023-Q1More consulting contracts, but fewer commissioned analyses and a swing to a lossAnnual report
「Although the number of regular consulting contracts increased, revenue declined because the number of commissioned analysis projects fell. Revenue was ¥25 million, down ¥0.2 million, or 1.2%, year on year. Segment loss (ordinary loss) was ¥1 million, compared with segment profit (ordinary profit) of ¥2 million in the same quarter of the previous year, due to higher personnel costs resulting from increased staffing and other factors.」
Although the number of regular consulting contracts increased, revenue fell 1.2% year on year and segment profit turned into a ¥1 million loss due to fewer commissioned analysis projects and higher personnel costs resulting from increased staffing. - FY2022-Q3AdvancedAnnual report
「Although external seminars were postponed due to the impact of the spread of COVID-19, revenue increased with the addition of the Cabinet Office's SIP program and new consulting contracts, alongside previously contracted JAXA subsidy programs and smart agriculture projects. Revenue was ¥76 million, up ¥19 million, or 35.0%, year on year.」
In the research and development and analysis business, the company secured the Cabinet Office's SIP program and new consulting contracts in addition to its existing JAXA subsidy programs and smart agriculture projects, increasing revenue by 35.0% year on year. - FY2022-Q1AdvancedAnnual report
「Although the number of commissioned analysis projects declined due to the impact of the spread of COVID-19, revenue from government research funding and other sources under JAXA subsidy programs and smart agriculture subsidy programs, as well as consulting projects, increased. Revenue was ¥25 million, up ¥8 million, or 53.3%, year on year.」
The research and development and analysis business secured JAXA subsidy programs, smart agriculture subsidy programs and consulting projects, increasing revenue by 53.3% year on year. - FY2021-Q3AdvancedAnnual report
「Segment profit (ordinary profit) increased by ¥2 million, or 36.5%, year on year to ¥8 million, as a result of thorough cost-cutting efforts, including consolidating operations and reviewing personnel costs.」
The research and development and analysis business consolidated operations and reviewed personnel costs, resulting in segment profit of ¥8 million, up 36.5% year on year. - FY2020ReframedAnnual report
「Going forward, we will consolidate research and development at 株式会社メディカル青果物研究所 and advance R&D efficiently.」
The restructuring policy is being changed from the previous division of responsibilities and collaboration between デザイナーフーズ and メディカル青果物研究所 to consolidating research and development at メディカル青果物研究所. - FY2020-Q3RestatedAnnual report
「Segment profit (ordinary profit) was ¥5 million, compared with a segment loss (ordinary loss) of ¥8 million in the same quarter of the previous year, due to lower outsourcing and personnel expenses resulting from improved operating efficiency, among other factors.」
The R&D and analysis business continued to generate profit of ¥5 million, compared with a loss of ¥8 million in the previous year, supported by lower outsourcing and personnel expenses resulting from improved operating efficiency. - FY2020-Q2AdvancedAnnual report
「Segment net sales were ¥62 million, a decrease of ¥1 million, or 3.0%, from the same quarter of the previous year, as the substantial decline in sales in the consulting division more than offset the steady increase in sales from analysis services. Segment profit (ordinary profit) was ¥5 million, compared with a segment loss (ordinary loss) of ¥9 million in the same quarter of the previous year, due to lower outsourcing and personnel expenses resulting from improved operating efficiency, among other factors.」
In the R&D and analysis business, lower outsourcing and personnel expenses resulting from improved operating efficiency led to an improvement from a loss of ¥9 million in the same quarter of the previous year to a profit of ¥5 million. The benefits of efficiency improvements after the reorganization are shown in the results for an additional quarter. - FY2020-Q1AdvancedAnnual report
「Segment net sales were ¥32 million, an increase of ¥2 million, or 6.7%, from the same quarter of the previous year, mainly because sales at Medical Produce Research Institute Co., Ltd., which primarily performs produce analysis, increased steadily. Segment profit (ordinary profit) was ¥3 million, compared with a segment loss (ordinary loss) of ¥8 million in the same quarter of the previous year, due to lower outsourcing and personnel expenses resulting from improved operating efficiency, in addition to higher sales.」
In the R&D and analysis business, lower outsourcing and personnel expenses resulting from improved operating efficiency led to an improvement from a loss of ¥8 million in the same quarter of the previous year to a profit of ¥3 million. - FY2019AdvancedAnnual report
「The result was ¥0 million, due to higher personnel expenses resulting from the strengthening of the analysis division, costs incurred in obtaining ISO 17025 laboratory accreditation, and other factors.」
Following the reorganization of the R&D and analysis businesses, efforts to strengthen the analysis division and obtain ISO 17025 laboratory accreditation moved into the implementation stage, with associated costs being incurred. - FY2019-Q3RestatedAnnual report
「The segment loss (ordinary loss) was ¥8 million, due to lower sales, higher personnel expenses resulting from the strengthening of the analysis division, costs incurred in connection with the relocation of Designer Foods Co., Ltd.'s laboratory, and other factors, compared with a segment loss (ordinary loss) of ¥6 million in the same quarter of the previous year.」
The company continued to report costs associated with strengthening the analysis division after the reorganization and relocating Designer Foods' laboratory, with the R&D and analysis business posting a loss of ¥8 million. - FY2019-Q1AdvancedAnnual report
「The segment loss (ordinary loss) was ¥8 million, due to lower sales, higher personnel expenses resulting from the strengthening of the analysis division, costs incurred in connection with the relocation of Designer Foods Co., Ltd.'s laboratory, and other factors, compared with an ordinary loss of ¥0 million in the same quarter of the previous year.」
Following the reorganization of the R&D division, strengthening of the analysis division and relocation of Designer Foods' laboratory moved into the implementation stage, with related costs being incurred. - FY2018AchievedAnnual report
「In June 2017, the R&D division, one of the Group's strengths, was split between and reorganized under consolidated subsidiary Designer Foods Co., Ltd. and Medical Produce Research Institute Co., Ltd.」
The split and reorganization of the R&D division under Designer Foods and Medical Produce Research Institute was explicitly stated to have been completed in June 2017. - FY2018-Q3AdvancedAnnual report
「The segment loss (ordinary loss) was ¥6 million, due to lower sales and costs incurred in connection with the reorganization of the R&D and analysis businesses, among other factors, compared with ordinary profit of ¥10 million in the same quarter of the previous year.」
Costs associated with the reorganization of the R&D and analysis businesses have actually been incurred, indicating that the split and reorganization of the R&D division is at the implementation stage. Completion itself is not explicitly stated. - FY2017First statedAnnual report
「To appropriately allocate the Group's management resources and further strengthen R&D, one of the Group's strengths, the R&D division will be split between and reorganized under Designer Foods Co., Ltd. and consolidated subsidiary Medical Produce Research Institute Co., Ltd., targeted for June 2017.」
The reorganization plan assigns Designer Foods to antioxidant research and new research fields, and Medical Produce Research Institute to freshness-retention technology and commissioned analysis.